Geneuro Stock

Geneuro Equity 2024

Geneuro Equity

-13.78 M EUR

Ticker

GNRO.PA

ISIN

CH0308403085

WKN

A2AHDP

In 2024, Geneuro's equity was -13.78 M EUR, a -1,041.31% increase from the 1.46 M EUR equity in the previous year.

Geneuro Aktienanalyse

What does Geneuro do?

Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Geneuro's Equity

Geneuro's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Geneuro's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Geneuro's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Geneuro's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Geneuro’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Geneuro stock

What is the equity of Geneuro this year?

Geneuro has equity of -13.78 M EUR this year.

What was the equity of Geneuro compared to the previous year?

The equity of Geneuro has increased/decreased by -1,041.31% decreased compared to the previous year.

What impact does a high equity have on investors of Geneuro?

A high equity is advantageous for investors of Geneuro as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Geneuro?

A low equity can be a risk for investors of Geneuro, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Geneuro affect the company?

An increase in equity of Geneuro can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Geneuro affect the company?

A reduction in equity of Geneuro can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Geneuro?

Some factors that can affect the equity of Geneuro include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Geneuro so important for investors?

The equity of Geneuro is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Geneuro take to change the equity?

To change equity, Geneuro can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Geneuro pay?

Over the past 12 months, Geneuro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geneuro is expected to pay a dividend of 0 EUR.

What is the dividend yield of Geneuro?

The current dividend yield of Geneuro is .

When does Geneuro pay dividends?

Geneuro pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Geneuro?

Geneuro paid dividends every year for the past 0 years.

What is the dividend of Geneuro?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Geneuro located?

Geneuro is assigned to the 'Health' sector.

Wann musste ich die Aktien von Geneuro kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Geneuro from 8/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Geneuro pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Geneuro in the year 2023?

In the year 2023, Geneuro distributed 0 EUR as dividends.

In which currency does Geneuro pay out the dividend?

The dividends of Geneuro are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Geneuro

Our stock analysis for Geneuro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geneuro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.